SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $1 |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | -585% |
| R&D Expenses | $9 | $7 | $8 | $8 |
| G&A Expenses | $0 | $3 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | $0 |
| Operating Expenses | $12 | $9 | $10 | $9 |
| Operating Income | -$13 | -$10 | -$11 | -$10 |
| % Margin | – | – | – | -8,726.3% |
| Other Income/Exp. Net | $58 | -$0 | $6 | -$1 |
| Pre-Tax Income | $45 | -$10 | -$5 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $5 | -$10 | -$5 | -$11 |
| % Margin | – | – | – | -9,934.5% |
| EPS | 0.5 | -1.09 | -0.56 | -1.23 |
| % Growth | 145.9% | -94.6% | 54.5% | – |
| EPS Diluted | -0.21 | -1.09 | -0.56 | -1.23 |
| Weighted Avg Shares Out | 11 | 9 | 9 | 9 |
| Weighted Avg Shares Out Dil | 78 | 9 | 9 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $46 | -$9 | -$4 | -$11 |
| % Margin | – | – | – | -9,187.7% |